Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleResponse to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL<sup>+</sup> human leukemia".AuthorsLai, Damian; Chen, Min; Su, Jiechuang; Liu, Xiaohu; Rothe, Katharina; Hu, Kaiji; Forrest, Donna L.; Eaves, Connie J.; Morin, Gregg B.; Jiang, XiaoyanAbstractLB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.SubjectsCANCER stem cells; PROTEIN-tyrosine kinases; BONE marrow cells; KINASE inhibitors; PROGENITOR cellsPublicationScience Translational Medicine, 2019, Vol 11, Issue 501, p1ISSN1946-6234Publication typeArticleDOI10.1126/scitranslmed.aav0819